VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+3.91%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$245M
AUM Growth
+$31M
(+15%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
12.58%
Top 10 Holdings %
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49
Top Buys
| 1 |
SPDR Bloomberg High Yield Bond ETF
JNK
|
$1.88M |
| 2 |
DocuSign
DOCU
|
$1.49M |
| 3 |
United Airlines
UAL
|
$1.47M |
| 4 |
Fortinet
FTNT
|
$1.35M |
| 5 |
Spotify
SPOT
|
$1.34M |
Top Sells
| 1 |
Applovin
APP
|
$1.45M |
| 2 |
Expedia Group
EXPE
|
$1.04M |
| 3 |
KKR & Co
KKR
|
$976K |
| 4 |
CME Group
CME
|
$974K |
| 5 |
Corpay
CPAY
|
$948K |
Sector Composition
| 1 | Financials | 29.48% |
| 2 | Technology | 14.86% |
| 3 | Healthcare | 14.81% |
| 4 | Industrials | 11.61% |
| 5 | Consumer Discretionary | 6.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
ArriVent BioPharma
AVBP
$819M
| $73.2K | 0.03% |
+2,747
| New | +$73.2K |
|
352
NewAmsterdam Pharma
NAMS
$3.04B
| $72.8K | 0.03% |
2,834
-1,904
| -40% | -$48.9K |
|
353
Neurogene
NGNE
$285M
| $72.8K | 0.03% |
3,183
+989
| +45% | +$22.6K |
|
354
Apogee Therapeutics
APGE
$2.26B
| $72.7K | 0.03% |
1,604
-534
| -25% | -$24.2K |
|
355
Merus
MRUS
$5.1B
| $72.2K | 0.03% |
1,716
+121
| +8% | +$5.09K |
|
356
Mineralys Therapeutics
MLYS
$2.31B
| $71.9K | 0.03% |
5,842
-1,425
| -20% | -$17.5K |
|
357
Nuvation Bio
NUVB
$1.33B
| $71.9K | 0.03% |
27,031
-3,790
| -12% | -$10.1K |
|
358
Pharvaris
PHVS
$1.48B
| $71.7K | 0.03% |
3,738
-1,351
| -27% | -$25.9K |
|
359
MoonLake Immunotherapeutics
MLTX
$3.77B
| $71.6K | 0.03% |
1,322
-840
| -39% | -$45.5K |
|
360
Prothena Corp
PRTA
$460M
| $71.3K | 0.03% |
5,148
+833
| +19% | +$11.5K |
|
361
Neumora Therapeutics
NMRA
$272M
| $71.2K | 0.03% |
6,720
-2,541
| -27% | -$26.9K |
|
362
Rocket Pharmaceuticals
RCKT
$354M
| $71.1K | 0.03% |
5,656
+1,628
| +40% | +$20.5K |
|
363
Summit Therapeutics
SMMT
$19.3B
| $71K | 0.03% |
3,979
-7,411
| -65% | -$132K |
|
364
Cullinan Oncology
CGEM
$413M
| $71K | 0.03% |
5,828
+1,600
| +38% | +$19.5K |
|
365
Xeris Biopharma Holdings
XERS
$1.27B
| $70.9K | 0.03% |
+20,910
| New | +$70.9K |
|
366
IDEAYA Biosciences
IDYA
$2.38B
| $70.9K | 0.03% |
2,758
+389
| +16% | +$10K |
|
367
89bio
ETNB
$1.32B
| $70.8K | 0.03% |
9,056
-867
| -9% | -$6.78K |
|
|
BLTE
368
Belite Bio
BLTE
$2.16B
| $70.8K | 0.03% |
1,122
-721
| -39% | -$45.5K |
|
|
TECX
369
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $70.8K | 0.03% |
+1,533
| New | +$70.8K |
|
370
CG Oncology
CGON
$2.52B
| $70.6K | 0.03% |
2,463
-185
| -7% | -$5.31K |
|
371
Xenon Pharmaceuticals
XENE
$3.02B
| $70.6K | 0.03% |
1,802
-623
| -26% | -$24.4K |
|
372
AbCellera Biologics
ABCL
$1.26B
| $70.6K | 0.03% |
24,099
-3,579
| -13% | -$10.5K |
|
|
CNTA
373
Centessa Pharmaceuticals
CNTA
$2.11B
| $70.6K | 0.03% |
4,214
-5,071
| -55% | -$84.9K |
|
374
MindMed
MNMD
$702M
| $70.5K | 0.03% |
+10,127
| New | +$70.5K |
|
375
Replimune Group
REPL
$494M
| $70.5K | 0.03% |
5,818
-3,921
| -40% | -$47.5K |
|